The objectives were to test the null hypotheses that (1) citrate, maltolate, and fluoride do not significantly influence oral Al bioavailability, Cmax or Tmax at an Al dose relevant to drinking water exposure; and (2) Al citrate and maltolate are absorbed intact from the gastrointestinal tract. Male Fisher rats were given 1 ml of solution intra-gastrically containing 1 nCi 26Al (65 nmol total Al) as the Al3+ ion, or as complexes with 14C-citrate, 14C-maltolate or fluoride, during concurrent 27Al iv infusion. Blood was repeatedly collected for serum 26Al, total Al and 14C quantification. Absorption parameters were estimated using WinNonlin. Al bioavailability, Cmax and Tmax from the ion, citrate, maltolate, and fluoride were 0.29 ± 0.11%, 0.61 ± 0.31%, 0.50 ± 0.25%, and 0.35 ± 0.10%; 659 ± 195, 1073 ± 250, 881 ± 356, and 880 ± 295 fg/ml; and 1.2 ± 0.9, 1.0 ± 1.1, 1.3 ± 1.0, and 1.0 ± 0.9 h (X ± SD) respectively. Serum 14C was ∼100 times higher than 26Al. The results suggest a non-significant enhancement of oral Al bioavailability by citrate and maltolate, some Al complex dissociation in the GI tract, and less absorption of Al than citrate or maltolate. The presence of citrate, maltolate and fluoride, at a similar molar concentration to Al, would not be expected to greatly influence Al absorption from drinking water.

Document Type


Publication Date


Notes/Citation Information

Published in Journal of Inorganic Biochemistry, v. 102, issue 4.

Copyright © 2008 Elsevier Inc. All rights reserved.

© 2008. This manuscript version is made available under the CC-BY-NC-ND 4.0 license https://creativecommons.org/licenses/by-nc-nd/4.0/.

The document available for download is the authors' post-peer-review final draft of the article.

Digital Object Identifier (DOI)


Funding Information

This research was supported by a grant from the US Environmental Protection Agency’s Science to Achieve Results (STAR) program (grant/cooperative agreement R-82978301 to Robert A. Yokel).